StockNews.com Begins Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report sent to investors on Wednesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

NASDAQ:CPIX opened at $1.76 on Wednesday. The stock’s fifty day moving average is $1.84 and its 200 day moving average is $1.88. Cumberland Pharmaceuticals has a fifty-two week low of $1.43 and a fifty-two week high of $2.36. The firm has a market capitalization of $24.96 million, a PE ratio of -4.00 and a beta of 0.16. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.11 and a current ratio of 1.28.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter. Cumberland Pharmaceuticals had a negative net margin of 15.87% and a positive return on equity of 6.84%. The company had revenue of $9.35 million for the quarter.

Institutional Trading of Cumberland Pharmaceuticals

An institutional investor recently bought a new position in Cumberland Pharmaceuticals stock. Bank of New York Mellon Corp purchased a new stake in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 75,268 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000. Bank of New York Mellon Corp owned 0.52% of Cumberland Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.